drugset / Trial / NCT06570811

Coenzyme Q10 and Chemotherapeutic Toxicity in Breast Cancer Patients

NCT06570811 ↗

Phase 2 Completed 40 enrolled Damanhour University
RandomizedParallel-groupOpen-labelTreatment

Summary

investigating the potential effect of Coenzyme Q10 in ameliorating and preventing the development of paclitaxel chemotherapeutic toxicity in breast cancer patients

Timeline

Start
2024-08-01
Primary completion
2025-03-10
Completion
2025-03-30

Outcome

Met primary endpoint

paper lower incidence of clinically relevant neuropathy, with grade ≥ 2 events occurring in 68% of the CoQ10 group versus 96% of controls (p = 0.01) PMID 42401951 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Coenzyme Q10 Other / unclassified 200 mg Oral